Paweł Bęczkowski and Emily Porter win the 2015 ABCD & Merial Young Scientist Awards.
Two ABCD & Merial Young Scientist Awards (AMYSA), for Basic research and for Clinical research were presented this year. The award ceremonies took place on the 2nd of July in Porto (Portugal), at the occasion of the congress of the International Society of Feline Medicine, organised by International Cat Care.
Paweł Bęczkowski: better understanding FIV infection
The 2015 AMYSA for Basic Research was presented to Dr Paweł Bęczkowski (31), a Polish resident in internal medicine (ECVIM) at the Small Animal Hospital at the University of Glasgow, UK. While studying at the University’s Centre for Virus Research, he focused on virus evolution in the disease progression of natural feline immunodeficiency virus (FIV). Relatively little is known about this process in naturally infected cats: why do some infected cats remain healthy while others rapidly progress to immunodeficiency? Dr Bęczkowski found this may be due to the relative stability of the FIV env gene.
“His work may help contribute to a better understanding of FIV infection, commented Dr Karin Moestl, chair of the European Advisory Board on Cats Diseases (ABCD). “This work is not only of veterinary significance and of clinical relevance, but also of comparative significance, as FIV serves as a valuable model for HIV infection.”
Emily Porter: FCoV genotypes and the development of FIP
The 2015 AMYSA for Clinical research went to Dr Emily Porter (27) of Bristol University, for her work on the relationship between FCoV genotypes and the development of FIP. Feline coronavirus infection (FIP) is one of most common causes of infectious disease in young cats housed in multicat environments. However, only a small percentage of infected cats go on to develop disease signs associated with FIP. Sequencing of the complete genomes of pathogenic and non-pathogenic viruses allowed identifying differences in the viruses that may contribute to pathogenicity.
“Emily Porter’s work contributes to the identification of virus mutations relating to the development of FIP”, commented Dr Jean-Christophe Thibault, Merial’s Technical Director for Biologicals (Europe, Middle East and Africa). “It also opens the door to the development of a robust reverse genetics system, contributing to the development of new diagnostic tools and to the construction of genetically modified recombinant viruses as candidate vaccine strains”.
ABCD & Merial Young Scientist Awards
The ABCD and Merial Young Scientist Awards, created in 2008, are funded by Merial and are presented to young scientists in veterinary or biomedical sciences, who have made an original contribution in the field of feline infectious diseases and/or immunology.
Applicants should have published their findings in a journal listed in PubMed or Web of Science or have had them accepted by another recognised assessing body. Candidates should be based in Europe, have completed a veterinary or biomedical curriculum, and be under 35 years of age at the time of application. Applications in the fields of both basic and applied sciences are welcome.
For further information, please contact Karin de Lange, ABCD secretary, karin.delange@abcd-vets.org
Notes to Editors:
Photo attached (credit: ©iCatCare). Caption ABCD & Merial Young Scientist Award winners Emily Porter (second left) and Paweł Bęczkowski (centre) flanked by Jean-Christophe Thibault (Merial, at left), Karin Moestl (ABCD chair) and Claire Bessant (iCatCare, on the right)
The European Advisory Board on Cat Diseases (ABCD) is an independent panel of 17 leading veterinarians from eleven European countries, with an expertise in immunology, vaccinology and/or feline medicine. The ABCD was set up to compile guidelines for the prevention and management of major feline infectious diseases in Europe, based on current scientific knowledge. For more information, please visit www.abcdcatsvets.org or www.abcd-vets.org.
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs 6,100 people and operates in more than 150 countries worldwide, with over $2 billion of sales in 2014. Merial is a Sanofi company. For more information, please see http://www.merial.com.
